Generic Product News
Clindamycin Phosphate and Benzoyl Peroxide 1.2%/5% Topical Gel
Marketed by: Perrigo Company (Allegan, MI)
Compared to: Duac Gel (Stiefel, a GSK Company)
Indication: Perrigo Company has received final approval from the FDA for its Clindamycin Phosphate and Benzoyl Peroxide 1.2%/5% Topical Gel. The product is indicated for topical treatment of inflammatory acne vulgaris. Patients should avoid contact with the eyes and mucous membranes when using Clindamycin Phosphate and Benzoyl Peroxide 1.2%/5% Topical Gel, and excessive or prolonged exposure to sunlight should be avoided.
Dosage Form: Topical gel: clindamycin phosphate/benzoyl peroxide 1.2%/5%
For More Information: www.perrigo.com
Marketed by: Teva Pharmaceuticals (Philadelphia, PA)
Compared to: Symbyax (Eli Lilly and Company)
Indication: Teva Pharmaceuticals announced the launch of Olanzapine and Fluoxetine Capsules USP, a generic version of Eli Lilly’s Symbyax. It is indicated for the acute treatment of treatment-resistant depression and for the treatment of depression caused by bipolar I disorder. It is not indicated for treatment of dementia-related psychosis, as olanzapine can cause heart failure, sudden death, or pneumonia in older adults.
Dosage Form: Capsules: 6 mg/25 mg, 12 mg/25 mg, 6 mg/50 mg, 12 mg/50 mg
For More Information: www.tevausa.com
Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended- Release Suspension
Marketed by: Cornerstone Therapeutics (Cary, NC)
Compared to: Tussionex Pennkinetic (UCB Group) Indication: Cornerstone Therapeutics announced the approval of its generic version of UCB’s Tussionex Pennkinetic suspension. The combination product contains hydrocodone polistirex and chlorpheniramine polistirex and is indicated for the treatment of cough and upper respiratory symptoms caused by cold or allergies. The product, a Schedule III narcotic, is contraindicated in children younger than 6 years due to potentially fatal respiratory depression.
Dosage Form: Each 5 mL contains the equivalent of 10 mg hydrocodone bitartrate and 8 mg chlorpheniramine maleate
For More Information: www.crtx.com
Marketed by: Sandoz (Princeton, NJ)
Compared to: Vfend (Pfizer, Inc)
Indication: Sandoz announced the introduction of voriconazole injection, a generic version of Pfizer’s Vfend. It is meant to treat fungal infections caused by yeast or other fungi, and works by blocking fungal cell wall growth. It may also be used to treat serious fungal infections in patients who cannot tolerate other treatments. It is indicated for use in patients 12 years and older for treatment of fungal infections of the blood and body.
Dosage Form: Lyophilized powder for injection: 200 mg; tablets: 50 and 200 mg
For More Information: www.sandoz.com